Skip Nav Destination
Issues
1 January 2008
-
Cover Image
Cover Image
A histologic section of a MEN 1 pituitary tumor following administration of an anti-VEGF-A antibody. Treatment with anti-VEGF-A resulted in a 3.7-fold inhibition of the pituitary tumor growth and increased mean tumor doubling-free survival compared with mice treated with a control antibody. Vessel density was reduced by anti-VEGF-A treatment to 46% that of control IgG-treated tumors.For further details, please see the article by Korsisaari and associates on page 249 of this issue. - PDF Icon PDF LinkTable of Contents
ISSN 1078-0432
EISSN 1557-3265
Editorials
Perspectives
Reviews
Human Cancer Biology
Imaging, Diagnosis, Prognosis
Impact of E2F-1 Expression on Clinical Outcome of Gastric Adenocarcinoma Patients with Adjuvant Chemoradiation Therapy
Jeeyun Lee; Cheol Keun Park; Joon Oh Park; Taekyu Lim; Young Suk Park; Ho Yeong Lim; Inkyoung Lee; Tae Sung Sohn; Jae Hyung Noh; Jin Seok Heo; Sung Kim; Do Hoon Lim; Kyoung-Mee Kim; Won Ki Kang
Evaluation of Promoter Hypermethylation Detection in Body Fluids as a Screening/Diagnosis Tool for Head and Neck Squamous Cell Carcinoma
André Lopes Carvalho; Carmen Jeronimo; Michael M. Kim; Rui Henrique; Zhe Zhang; Mohammad O. Hoque; Steve Chang; Mariana Brait; Chetan S. Nayak; Wei-Wen Jiang; Quia Claybourne; Yutaka Tokumaru; Juna Lee; David Goldenberg; Elizabeth Garrett-Mayer; Steven Goodman; Chul-so Moon; Wayne Koch; William H. Westra; David Sidransky; Joseph A. Califano
Axl and Growth Arrest–Specific Gene 6 Are Frequently Overexpressed in Human Gliomas and Predict Poor Prognosis in Patients with Glioblastoma Multiforme
Markus Hutterer; Pjotr Knyazev; Ariane Abate; Markus Reschke; Hans Maier; Nadia Stefanova; Tatjana Knyazeva; Verena Barbieri; Markus Reindl; Armin Muigg; Herwig Kostron; Guenther Stockhammer; Axel Ullrich
Identification of Patients with (Atypical) MUTYH-Associated Polyposis by KRAS2 c.34G > T Prescreening Followed by MUTYH Hotspot Analysis in Formalin-Fixed Paraffin-Embedded Tissue
Marjo van Puijenbroek; Maartje Nielsen; Carli M.J. Tops; Hans Halfwerk; Hans F.A. Vasen; Marjan M. Weiss; Tom van Wezel; Frederik J. Hes; Hans Morreau
Cancer Therapy: Clinical
Fludarabine, Cyclophosphamide, and Mitoxantrone as Initial Therapy of Chronic Lymphocytic Leukemia: High Response Rate and Disease Eradication
Francesc Bosch; Ana Ferrer; Neus Villamor; Marcos González; Javier Briones; Eva González-Barca; Eugenia Abella; Santiago Gardella; Lourdes Escoda; Elena Pérez-Ceballos; Antoni Asensi; Ma José Sayas; Llorenç Font; Albert Altés; Ana Muntañola; Paola Bertazzoni; María Rozman; Marta Aymerich; Eva Giné; Emili Montserrat
Radiotherapy in Lung Adenocarcinoma with Brain Metastases: Effects of Activating Epidermal Growth Factor Receptor Mutations on Clinical Response
Chien-Hung Gow; Chun-Ru Chien; Yih-Leong Chang; Yueh-Hsia Chiu; Sung-Hsin Kuo; Jin-Yuan Shih; Yeun-Chung Chang; Chong-Jen Yu; Chih-Hsin Yang; Pan-Chyr Yang
Phase I Immunotherapeutic Trial with Long Peptides Spanning the E6 and E7 Sequences of High-Risk Human Papillomavirus 16 in End-Stage Cervical Cancer Patients Shows Low Toxicity and Robust Immunogenicity
Gemma G. Kenter; Marij J.P. Welters; A.Rob P.M. Valentijn; Margriet J.G. Löwik; Dorien M.A. Berends-van der Meer; Annelies P.G. Vloon; Jan W. Drijfhout; Amon R. Wafelman; Jaap Oostendorp; Gert Jan Fleuren; Rienk Offringa; Sjoerd H. van der Burg; Cornelis J.M. Melief
Induction of Tumor-Specific CD4+ and CD8+ T-Cell Immunity in Cervical Cancer Patients by a Human Papillomavirus Type 16 E6 and E7 Long Peptides Vaccine
Marij J.P. Welters; Gemma G. Kenter; Sytse J. Piersma; Annelies P.G. Vloon; Margriet J.G. Löwik; Dorien M.A. Berends-van der Meer; Jan W. Drijfhout; A. Rob P.M. Valentijn; Amon R. Wafelman; Jaap Oostendorp; Gert Jan Fleuren; Rienk Offringa; Cornelis J.M. Melief; Sjoerd H. van der Burg
Clinical and Molecular Responses in Lung Cancer Patients Receiving Romidepsin
David S. Schrump; Maria R. Fischette; Dao M. Nguyen; Ming Zhao; Xinmin Li; Tricia F. Kunst; Ana Hancox; Julie A. Hong; G. Aaron Chen; Evgeny Kruchin; John J. Wright; Douglas R. Rosing; Alex Sparreboom; William D. Figg; Seth M. Steinberg
A Phase II Clinical Trial of Sorafenib in Androgen-Independent Prostate Cancer
William L. Dahut; Charity Scripture; Edwin Posadas; Lokesh Jain; James L. Gulley; Philip M. Arlen; John J. Wright; Yunkai Yu; Liang Cao; Seth M. Steinberg; Jeanny B. Aragon-Ching; Jürgen Venitz; Elizabeth Jones; Clara C. Chen; William D. Figg
Phase I Pharmacokinetic/Pharmacodynamic Study of EKB-569, an Irreversible Inhibitor of the Epidermal Growth Factor Receptor Tyrosine Kinase, in Combination with Irinotecan, 5-Fluorouracil, and Leucovorin (FOLFIRI) in First-Line Treatment of Patients with Metastatic Colorectal Cancer
Gunnar Folprecht; Josep Tabernero; Claus-Henning Köhne; Charles Zacharchuk; Luis Paz-Ares; Federico Rojo; Susan Quinn; Esther Casado; Ramon Salazar; Richat Abbas; Chantal Lejeune; Irene Marimón; Jordi Andreu; Ulrike Ubbelohde; Hernan Cortes-Funes; Jose Baselga
Phase III Prevention Trial of Fenretinide in Patients with Resected Non–Muscle-Invasive Bladder Cancer
Anita L. Sabichi; Seth P. Lerner; E. Neely Atkinson; H. Barton Grossman; Nancy P. Caraway; Colin P. Dinney; David F. Penson; Surena Matin; Ashish Kamat; Louis L. Pisters; Daniel W. Lin; Ruth L. Katz; Dean E. Brenner; George P. Hemstreet, III; Mary Wargo; Archie Bleyer; William H. Sanders; John L. Clifford; Howard L. Parnes; Scott M. Lippman
Cancer Therapy: Preclinical
The Mitogen-Activated Protein/Extracellular Signal-Regulated Kinase Kinase Inhibitor AZD6244 (ARRY-142886) Induces Growth Arrest in Melanoma Cells and Tumor Regression When Combined with Docetaxel
Nikolas K. Haass; Katrin Sproesser; Thiennga K. Nguyen; Rooha Contractor; C. Angelica Medina; Katherine L. Nathanson; Meenhard Herlyn; Keiran S.M. Smalley
Blocking Vascular Endothelial Growth Factor-A Inhibits the Growth of Pituitary Adenomas and Lowers Serum Prolactin Level in a Mouse Model of Multiple Endocrine Neoplasia Type 1
Nina Korsisaari; Jed Ross; Xiumin Wu; Marcin Kowanetz; Navneet Pal; Linda Hall; Jeffrey Eastham-Anderson; William F. Forrest; Nicholas Van Bruggen; Franklin V. Peale; Napoleone Ferrara
Cyclophosphamide Facilitates Antitumor Efficacy against Subcutaneous Tumors following Intravenous Delivery of Reovirus
Jian Qiao; Hongxun Wang; Timothy Kottke; Christine White; Katie Twigger; Rosa Maria Diaz; Jill Thompson; Peter Selby; Johann de Bono; Alan Melcher; Hardev Pandha; Matt Coffey; Richard Vile; Kevin Harrington
Combining Agents that Target the Tumor Microenvironment Improves the Efficacy of Anticancer Therapy
Joseph A. Blansfield; Diana Caragacianu; H. Richard Alexander, III; Michael A. Tangrea; Shane Y. Morita; Dominique Lorang; Peter Schafer; George Muller; David Stirling; Richard E. Royal; Steven K. Libutti
Antitumor Effects of Systemically Delivered Adenovirus Harboring Trans-Splicing Ribozyme in Intrahepatic Colon Cancer Mouse Model
Jin-Sook Jeong; Seong-Wook Lee; Seung-Hee Hong; Yoon-Jong Lee; Haeng-Im Jung; Kyung-Sook Cho; Hye-Hyun Seo; Sang-Jin Lee; Sohee Park; Min-Sun Song; Chang-Min Kim; In-Hoo Kim
Correction
Acknowledgment to Reviewers
Advertisement
Email alerts
NOTICE: This notice serves to inform the reader that, in 2023, AACR received a donation by Pfizer of the rights to royalties from the sale within the United States of Bavencio® (avelumab), a pharmaceutical owned by Merck. If any resulting funds are received, they would not be used to directly support any specific publication or author. If an individual article is published that deals with this particular drug, such article will include standard financial disclosures per AACR journal policy. For more detail regarding AACR’s established policies for authors, please go to https://aacrjournals.org/pages/editorial-policies#coi.
RSS Feeds